Korro Bio Q2 FY26 net loss narrows to USD 18.92 million; revenue posts no collaboration revenue

Reuters2026/08/06 11:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Korro posted a net loss of USD 18.9 million, narrowing from USD 25.8 million a year earlier; loss per share improved to USD 1.07 from USD 2.74.
Research and development expense fell to USD 13.6 million from USD 20.1 million; general and administrative costs eased to USD 6.5 million from USD 7.3 million.
Revenue was no revenue versus USD 1.5 million, reflecting a 12-month pause of its Novo Nordisk collaboration agreed in November 2025.
Cash, cash equivalents and marketable securities rose to USD 137.9 million from USD 85.2 million at Dec. 31, 2025, extending runway into the second half of 2028.
KRRO-121 remains on track for a first-in-human trial in the second half of 2026; KRRO-111 was named a development candidate for Alpha-1 Antitrypsin Deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Korro Bio Q2 FY26 net loss narrows to USD 18.92 million; revenue posts no collaboration revenue

You may also like

Crypto prices